NIMble innovation - a networked model for public antibiotic trials

Rebecca Glover, Andrew Singer, Adam Roberts and Claas Kirchhelle

No vp8mj, SocArXiv from Center for Open Science

Abstract: Antibiotic research and development (R&D) is at an inflection point. Faced with ongoing problems with commercial innovation, we argue for a networked public approach to sustainably moving promising compounds through clinical trials. We propose a global public infrastructure of institutes tasked with 1) conducting all trial stages up to market authorization, including small-scale compound production; 2) negotiating licensing agreements for global production and distribution by industry partners; 3) using public purchasing agreements or subscription models to ensure commercially viable drug production at equitable prices. We invite stakeholders to consider our Networked Institute Model’s (NIM) benefits for unblocking the antibiotic pipeline.

Date: 2021-06-25
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://osf.io/download/60d4de8ef38858009d9db5f3/

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:osf:socarx:vp8mj

DOI: 10.31219/osf.io/vp8mj

Access Statistics for this paper

More papers in SocArXiv from Center for Open Science
Bibliographic data for series maintained by OSF ().